CN1445220A - Lactone category compound of sweetsop as well as new usage in medicines and its preparing method - Google Patents
Lactone category compound of sweetsop as well as new usage in medicines and its preparing method Download PDFInfo
- Publication number
- CN1445220A CN1445220A CN 03111501 CN03111501A CN1445220A CN 1445220 A CN1445220 A CN 1445220A CN 03111501 CN03111501 CN 03111501 CN 03111501 A CN03111501 A CN 03111501A CN 1445220 A CN1445220 A CN 1445220A
- Authority
- CN
- China
- Prior art keywords
- coch
- carbon
- preparation
- och
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及番荔枝内酯类化合物及医药新用途和制备方法,它是对分化的C2C12成肌细胞摄取葡萄糖及产生乳酸的能力具有促进活性,提示具有降糖作用,可单独应用或者合用或与适宜的赋形剂结合,制成口服剂型或非口服剂型的抗糖尿病药物,用于II型或I型糖尿病的治疗。其制备方法包括从天然植物原料中分离及化学合成等手段,经浓缩,萃取,洗脱,色谱分离等工艺制成。其分子结构中含有至少一个饱和或不饱和五员内酯环结构和一个长的多取代的脂肪链结构。The present invention relates to annona lactone compound and its new medicinal use and preparation method. It has promoting activity on the ability of differentiated C2C12 myoblasts to absorb glucose and produce lactic acid, suggesting that it has hypoglycemic effect, and can be used alone or in combination or with Appropriate excipients are combined to prepare anti-diabetic drugs in oral dosage form or non-oral dosage form, which are used for the treatment of type II or type I diabetes. Its preparation method includes separation from natural plant raw materials and chemical synthesis, etc., and is prepared through processes such as concentration, extraction, elution, and chromatographic separation. Its molecular structure contains at least one saturated or unsaturated five-membered lactone ring structure and a long multi-substituted aliphatic chain structure.
Description
技术领域:Technical field:
本发明涉及医药技术领域,确切地说它是一种番荔枝内酯类化合物及医药新用途和制备方法。The invention relates to the technical field of medicine, in particular to an annona lactone compound, a new medicine application and a preparation method.
背景技术:Background technique:
番荔枝科(Annona Linn.)植物,所含成分主要有番荔枝内酯(actogenins)、苯乙烯内酯、多氧环己烯、生物碱、黄酮及萜类等类型化合物。目前研究的热点是该科植物所含番荔枝内酯类化合物的抗癌和杀虫活性。从1982年第一个番荔枝内酯报道以来,迄今已发现该类化合物300多个,被认为是紫杉醇后又一类具有强抗癌活性的天然化合物。我们以分化的C2C12成肌细胞对葡萄糖的摄取功能和产生乳酸的能力为指标对一千余种天然药用植物的提取物进行抗糖尿病活性筛选,发现了数种活性较强的提取物,其中包含多种番荔枝科植物的提取物。并利用活性追踪的方法从刺果番荔枝、金平哥纳香等提取物中分离得到数种具有较强活性的番荔枝内酯类化合物。Annona Linn. plants contain mainly actogenins, styrylactones, polyoxanes, alkaloids, flavonoids and terpenoids. The current research hotspot is the anticancer and insecticidal activities of the annonaceous lactone compounds contained in the plants of this family. Since the first annonaceolide was reported in 1982, more than 300 such compounds have been discovered so far, and it is considered to be another class of natural compounds with strong anticancer activity after paclitaxel. We used the glucose uptake function of differentiated C2C12 myoblasts and the ability to produce lactic acid as indicators to screen the extracts of more than a thousand kinds of natural medicinal plants for anti-diabetic activity, and found several extracts with strong activity, among which Contains extracts of various Annonaceae plants. And use the method of activity tracking to isolate several kinds of annona lactone compounds with strong activity from the extracts of soursop and Jinping Gornarica.
发明内容:Invention content:
本发明的目的是提供番荔枝内酯类化合物及医药新用途和制备方法,上述化合物可望开发成一种新型的天然降糖药物,用于糖尿病的治疗。其特征在于:番荔枝内酯类化合物分子中含有至少一个饱和或不饱和五员内酯环结构和一个长的多取代的脂肪链结构,可以是如下结构之一:The purpose of the present invention is to provide annona lactone compound and its new medical application and preparation method. The compound is expected to be developed into a new type of natural hypoglycemic drug for the treatment of diabetes. It is characterized in that: the anemone lactone compound molecule contains at least one saturated or unsaturated five-membered lactone ring structure and a long multi-substituted aliphatic chain structure, which can be one of the following structures:
结构I: Structure I:
R1可为CH3、CH2OH、CH2COCH3中的一种;R2或R3可为H、O、OH、OCOCH3中的一种(如为O时,应与所连接的碳形成羰基);x、m或n可为0~10。R 1 can be one of CH 3 , CH 2 OH, CH 2 COCH 3 ; R2 or R3 can be one of H, O, OH, OCOCH3 (if it is O, it should form a carbonyl group with the connected carbon ); x, m or n can be 0-10.
结构II: Structure II:
R1可为CH3、CH2OH、CH2COCH3中的一种;m或n可为0~10。R 1 can be one of CH 3 , CH 2 OH and CH 2 COCH 3 ; m or n can be 0-10.
结构III: Structure III:
R1可为CH3、CH2OH、CH2COCH3中的一种;R2~R7、可为O、OH、OCH3、OCOCH3中的一种(如为O时,应与所连接的碳形成羰基);m或n可为0~10。R 1 can be one of CH 3 , CH 2 OH, CH 2 COCH 3 ; R 2 ~ R 7 can be one of O, OH, OCH 3 , OCOCH3 (if it is O, it should be connected with carbon to form a carbonyl); m or n can be 0-10.
结构IV: Structure IV:
R1可为CH3、CH2OH、CH2COCH3中的一种;R2~R9可为H、O、OH、OCH3、OCOCH3中的一种(如为O时,应与所连接的碳形成羰基);m、n、x、y、z可为0~10。R 1 can be one of CH 3 , CH 2 OH, CH 2 COCH 3 ; R2 ~ R9 can be one of H, O, OH, OCH3, OCOCH3 (if it is O, it should be connected with the connected carbon form a carbonyl group); m, n, x, y, z can be 0-10.
结构V: Structure V:
R1可为CH3、CH2OH、CH2COCH3中的一种;R2~R7、可为H、O、OH、OCH3、OCOCH3 R 1 can be one of CH 3 , CH 2 OH, CH 2 COCH 3 ; R 2 ~ R 7 can be H, O, OH, OCH 3 , OCOCH 3
中的一种(为O时,与所连接的碳形成羰基);m、n、x、y可为0~10。One of (when it is O, it forms a carbonyl group with the connected carbon); m, n, x, y can be 0-10.
结构VI: Structure VI:
R1可为CH3、CH2OH、CH2COCH3中的一种;R2或R3、可为H、O、OH、OCH3、OCOCH3中的一种(为O时,与所连接的碳形成羰基);m或n可为0~10。R 1 can be one of CH 3 , CH 2 OH, CH 2 COCH 3 ; R 2 or R 3 can be one of H, O, OH, OCH 3 , OCOCH 3 (when it is O, the same The attached carbon forms a carbonyl); m or n can be 0-10.
结构VII: Structure VII:
R1可为CH3、CH2OH、CH2COCH3中的一种;R2~R4、可为H、O、OH、OCH3、OCOCH3 R 1 can be one of CH 3 , CH 2 OH, CH 2 COCH 3 ; R 2 ~ R 4 can be H, O, OH, OCH 3 , OCOCH 3
中的一种(为O时,与所连接的碳形成羰基);m或n可为0~10。One of them (when it is O, it forms a carbonyl group with the connected carbon); m or n can be 0-10.
结构VIII: Structure VIII:
R1可为CH3、CH2OH、CH2COCH3中的一种;R2或R3、可为H、O、OH,OCH3、OCOCH3 R 1 can be one of CH 3 , CH 2 OH, CH 2 COCH 3 ; R 2 or R 3 can be H, O, OH, OCH 3 , OCOCH 3
中的一种(为O时,与所连接的碳形成羰基);m或n可为0~10。One of them (when it is O, it forms a carbonyl group with the connected carbon); m or n can be 0-10.
结构IX: Structure IX:
R1可为CH3、CH2OH、CH2COCH3中的一种;R2或R3、可为H、O、OH、OCH3、OCOCH3 R 1 can be one of CH 3 , CH 2 OH, CH 2 COCH 3 ; R 2 or R 3 can be H, O, OH, OCH 3 , OCOCH 3
中的一种(为O时,与所连接的碳形成羰基);m或n可为0~10。One of them (when it is O, it forms a carbonyl group with the connected carbon); m or n can be 0-10.
本发明不仅仅限于上述九种结构类型,还应包括其他番荔枝内酯类化合物(acetogenins)。The present invention is not limited to the above nine structural types, but also includes other acetogenins.
番荔枝内酯类化合物的制备方法可以是从天然物中分离,也可以是化学合成,也可以是在某个番荔枝内酯化合物的基础上进行结构修饰或生物转化等。以下是从天然植物中分离番荔枝内酯类化合物时的操作方法:The preparation method of the anemone lactone compound may be separation from natural products, chemical synthesis, or structural modification or biotransformation on the basis of a certain anemone lactone compound. The following is the procedure for isolating annonaceous lactones from natural plants:
以番荔枝科植物的枝叶、树干、根、果皮或种子为原料,采用溶剂提取法,树脂吸附法等工艺中的一种或两种工艺制成浓缩提取物,然后用氯仿、乙醚等有机溶剂萃取。萃取物经硅胶柱色谱分离。硅胶柱中填充的硅胶粒度可为60~300目(最佳粒度为100~200目),用环己烷、氯仿、丙酮、甲醇等组成的由小极性到大极性的洗脱溶剂洗脱,将得到的含有番荔枝内酯化合物部分利用高效液相色谱(正相硅胶色谱柱或反相ODS色谱柱)分离制备番荔枝内酯。Using the branches, leaves, trunks, roots, peels or seeds of Annonaceae plants as raw materials, one or two of the processes such as solvent extraction and resin adsorption are used to make concentrated extracts, and then organic solvents such as chloroform and ether are used to make concentrated extracts. extraction. The extract was separated by silica gel column chromatography. The particle size of the silica gel filled in the silica gel column can be 60-300 mesh (the optimal particle size is 100-200 mesh), and it is washed with an elution solvent composed of cyclohexane, chloroform, acetone, methanol, etc. from small polarity to large polarity. Take off, the obtained annona lactone-containing compound part utilizes high performance liquid chromatography (normal phase silica gel chromatographic column or reverse phase ODS chromatographic column) to separate and prepare annona lactone.
所采用的溶剂提取法中,可选用水或甲醇、乙醇、丙醇、丁醇、戊醇、丙酮、乙酸乙酯、甲酸乙酯、氯仿、二氯甲烷、乙醚等有机溶剂,或两种或多种互溶的混合溶剂,在室温下浸渍提取或用超声提取或加热状态下的回流提取。提取次数可为一次,也可为多次。In the solvent extraction method adopted, organic solvents such as water or methanol, ethanol, propanol, butanol, amyl alcohol, acetone, ethyl acetate, ethyl formate, chloroform, methylene chloride, ether, or two or more A variety of miscible mixed solvents can be extracted by dipping at room temperature or by ultrasonic extraction or reflux extraction under heating. The number of extractions can be one time or multiple times.
所采用的溶剂萃取法中,可将上述得到的提取物悬浮于水中用适宜溶剂(丁醇、戊醇、乙酸乙酯、甲酸乙酯、氯仿、二氯甲烷、乙醚等)直接进行萃取。萃取次数可为一次,也可为多次。In the solvent extraction method adopted, the extract obtained above can be suspended in water and extracted directly with a suitable solvent (butanol, pentanol, ethyl acetate, ethyl formate, chloroform, dichloromethane, ether, etc.). The number of times of extraction can be one time or multiple times.
所采用的树脂法,大孔吸附树脂等。如,水、醇或醇水提取物可用大孔吸附树脂进行处理,弃去水洗脱部分,收集醇洗脱部分。The resin method used, macroporous adsorption resin, etc. For example, water, alcohol or alcohol-water extract can be treated with macroporous adsorption resin, the water eluted part is discarded, and the alcohol eluted part is collected.
本发明番荔枝内酯类化合物的分离方法还包括二氧化碳超临界提取分离。The separation method of the anemone lactone compound of the present invention also includes supercritical extraction and separation of carbon dioxide.
将制备的番荔枝内酯类化合物作为抗糖尿病有效成分,可单独应用或者合用,或与适宜的赋形剂等结合,按照常规方法制成口服剂型或非口服剂型(针剂、喷雾剂、贴剂等)应用于糖尿病的治疗。The prepared anemone lactone compounds can be used as anti-diabetic active ingredients, which can be used alone or in combination, or combined with suitable excipients, etc., to make oral dosage forms or non-oral dosage forms (injections, sprays, patches, etc.) according to conventional methods. etc.) for the treatment of diabetes.
本发明的优点是:本发明利用番荔枝内酯类化合物作为抗糖尿病有效成份,具有天然药物特点,可望开发成新型天然降糖药物,用于II型式I型糖尿病的治疗。另外,本发明工艺简单,易于放大,便于工业化生产。The advantage of the present invention is that: the present invention utilizes anemone lactone compound as the anti-diabetic active ingredient, has the characteristics of natural medicine, and is expected to be developed into a new type of natural hypoglycemic medicine for the treatment of type II type I diabetes. In addition, the process of the invention is simple, easy to scale up, and convenient for industrialized production.
附图说明:Description of drawings:
图1为本发明cis-Annonacin与arianacin对分化的C2C12细胞摄取葡萄糖的促进作用(n=4)测试结果表Fig. 1 is the test result table of the promoting effect (n=4) of cis-Annonacin and arianacin of the present invention on the uptake of glucose by differentiated C2C12 cells
图2为本发明Leiogenin和Gigantriocin对分化的C2C12细胞摄取葡萄糖及生成乳酸的促进作用(n=4)测试结果表Fig. 2 is the test result table of Leiogenin and Gigantriocin of the present invention on glucose uptake and lactic acid production in differentiated C2C12 cells (n=4)
具体实施方式:Detailed ways:
实施例1:刺果番荔枝种子1kg,粉碎,用10倍量的95%乙醇回流提取2小时,过滤,浓缩至半固体状提取物。随用水混悬,氯仿萃取。将所得氯仿萃取物与三倍量的硅胶(100~140目)拌样,用50倍量的硅胶(100~200目)进行柱层析,将含有番荔枝内酯类化合物部分进行高效液相色谱制备(正相SiO2填料色谱柱:反相ODS填料色谱柱)得到cis-annonacin(32mg),arianacin(14mg)annonacin-10-one(11mg),gigantetronein(6mg),gigantetrocinA(4mg),goniothalamicin(23mg)。所得部分化合物对分化的C2C12成肌细胞摄取葡萄糖的能力有促进作用,测试结果如表1所示。cis-Annonacin的平面化学结构:Arianacin的平面化学结构: Example 1: 1 kg of soursop seeds, pulverized, extracted with 10 times the amount of 95% ethanol under reflux for 2 hours, filtered, and concentrated to a semi-solid extract. Suspended with water, extracted with chloroform. The obtained chloroform extract was mixed with three times the amount of silica gel (100-140 mesh), and 50 times the amount of silica gel (100-200 mesh) was used for column chromatography, and the part containing annona lactone compounds was subjected to high-performance liquid phase analysis. Chromatographic preparation (normal phase SiO2 packing chromatographic column: reverse phase ODS packing chromatographic column) obtained cis-annonacin (32mg), arianacin (14mg) annonacin-10-one (11mg), gigantetronein (6mg), gigantetrocinA (4mg), goniothalamicin ( 23mg). Some of the obtained compounds can promote the glucose uptake ability of differentiated C2C12 myoblasts, and the test results are shown in Table 1. The planar chemical structure of cis-Annonacin: Planar chemical structure of Arianacin:
实施例2:金平哥纳香(Goniothalamus Leiocarpus)的干燥根2kg,粉碎,用10倍量的氯仿回流提取2小时,过滤,浓缩至半固体状提取物。将所得提取取物与三倍量的硅胶(100~140目)拌样,用50倍量的硅胶(100~200目)进行柱层析,将含有番荔枝内酯类化合物部分进行高效液相色谱制备(正相SiO2填料色谱柱或反相ODS填料色谱柱)得到Leiogenin和Gigantriocin。它们对分化的C2C12成肌细胞摄取葡萄糖及生成乳酸能力的促进作用如表2所示。Leiogenin的化学结构:Gigantriocin的化学结构: Example 2: 2 kg of dried root of Goniothalamus Leiocarpus was pulverized, extracted with 10 times the amount of chloroform under reflux for 2 hours, filtered, and concentrated to a semi-solid extract. The obtained extract was mixed with three times the amount of silica gel (100-140 mesh), and 50 times the amount of silica gel (100-200 mesh) was used for column chromatography, and the part containing anemone lactone compounds was subjected to high-performance liquid chromatography. Chromatographic preparation (normal phase SiO2 packed column or reversed phase ODS packed column) yielded Leiogenin and Gigantriocin. Table 2 shows their promoting effects on the ability of differentiated C2C12 myoblasts to uptake glucose and produce lactic acid. The chemical structure of Leiogenin: Chemical structure of Gigantriocin:
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03111501 CN1255397C (en) | 2003-04-21 | 2003-04-21 | Lactone category compound of sweetsop as well as new usage in medicines and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03111501 CN1255397C (en) | 2003-04-21 | 2003-04-21 | Lactone category compound of sweetsop as well as new usage in medicines and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1445220A true CN1445220A (en) | 2003-10-01 |
| CN1255397C CN1255397C (en) | 2006-05-10 |
Family
ID=27814575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03111501 Expired - Fee Related CN1255397C (en) | 2003-04-21 | 2003-04-21 | Lactone category compound of sweetsop as well as new usage in medicines and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1255397C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101575324B (en) * | 2009-05-15 | 2011-05-25 | 贵州正鑫药业有限公司 | Preparation method for extracting anticancer valid-position medicine SHIKEMOXIN from sweetsop |
| CN106543159A (en) * | 2016-11-10 | 2017-03-29 | 南京中医药大学 | Epoxy type Annonaceousacetogenicompounds compounds with anti-tumor activity and preparation method and application |
| CN106543117A (en) * | 2016-11-10 | 2017-03-29 | 南京中医药大学 | With double tetrahydrofuran type Annonaceousacetogenicompounds compounds and preparation method and application between anti-tumor activity |
| CN107674065A (en) * | 2017-10-13 | 2018-02-09 | 江苏建康职业学院 | Annonaceous acetogenins and its application with antitumor activity |
| CN107753532A (en) * | 2017-11-07 | 2018-03-06 | 海南医学院 | A kind of soursop root extract and its anti-diabetes use |
| CN111184032A (en) * | 2020-01-10 | 2020-05-22 | 云南农业大学 | A kind of Jinghong gonaxiang nematicidal extract and its preparation method and application |
| CN111317750A (en) * | 2020-02-17 | 2020-06-23 | 江苏卫生健康职业学院 | Application of sweetsop seed total lactone in preparing medicine for preventing and treating diabetes |
-
2003
- 2003-04-21 CN CN 03111501 patent/CN1255397C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101575324B (en) * | 2009-05-15 | 2011-05-25 | 贵州正鑫药业有限公司 | Preparation method for extracting anticancer valid-position medicine SHIKEMOXIN from sweetsop |
| CN106543159A (en) * | 2016-11-10 | 2017-03-29 | 南京中医药大学 | Epoxy type Annonaceousacetogenicompounds compounds with anti-tumor activity and preparation method and application |
| CN106543117A (en) * | 2016-11-10 | 2017-03-29 | 南京中医药大学 | With double tetrahydrofuran type Annonaceousacetogenicompounds compounds and preparation method and application between anti-tumor activity |
| CN106543159B (en) * | 2016-11-10 | 2019-02-05 | 南京中医药大学 | Epoxidized annua lactone compound with antitumor activity and its preparation method and application |
| CN107674065A (en) * | 2017-10-13 | 2018-02-09 | 江苏建康职业学院 | Annonaceous acetogenins and its application with antitumor activity |
| CN107753532A (en) * | 2017-11-07 | 2018-03-06 | 海南医学院 | A kind of soursop root extract and its anti-diabetes use |
| CN111184032A (en) * | 2020-01-10 | 2020-05-22 | 云南农业大学 | A kind of Jinghong gonaxiang nematicidal extract and its preparation method and application |
| CN111184032B (en) * | 2020-01-10 | 2021-05-07 | 云南农业大学 | Goniothalamus affinis nematode killing extract as well as preparation method and application thereof |
| CN111317750A (en) * | 2020-02-17 | 2020-06-23 | 江苏卫生健康职业学院 | Application of sweetsop seed total lactone in preparing medicine for preventing and treating diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1255397C (en) | 2006-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105294623B (en) | A sesquiterpene lactone compound, its preparation method and application | |
| CN105859803B (en) | A kind of preparation method of galloyl glucose | |
| CN1445220A (en) | Lactone category compound of sweetsop as well as new usage in medicines and its preparing method | |
| CN1323797A (en) | Chinese chestnut flower flavone compound and its extraction process | |
| CN104387362B (en) | A kind of iridoidate compound, its preparation method and application | |
| CN113666902B (en) | Method for separating and preparing lignan derivatives from biota orientalis | |
| CN1368295A (en) | Nano medicine 'Xiangdan' and its preparing process | |
| CN108892657A (en) | A kind of iridoidate compound, preparation method and its application | |
| CN1911932A (en) | Method for separating and preparing Tripterygium wilfordii alkaloid monomer from tripterygium wilfordii by countercurrent chromatography | |
| CN1362191A (en) | Nano Folium Ginkgo medicine and its preparation | |
| CN1364551A (en) | Nano phlegm removing and cough arresting medicine and its preparing method | |
| CN1733069A (en) | Oral cavity spray containing two effective parts of compound red sage root formula and its preparation process | |
| CN112876366A (en) | Broom-like isoesterasum, preparation method and application thereof, and pharmaceutical composition | |
| CN1368349A (en) | Nano medicine 'Huodan Biyan' and its preparing process | |
| Wang | Study on integrated bioseparation technologies for mass taxane production | |
| CN110483544A (en) | A kind of Sesquiterpene lactones compound and its preparation method and application | |
| CN1362219A (en) | Nano Zhichuanling medicine for treating asthma and its preparation | |
| CN1362102A (en) | Nano shengqi medicine and its preparation | |
| CN1973856A (en) | Method of eliminating perilla ketone from perilla leaf extract | |
| CN1368121A (en) | Nano medicine 'Jinzeguanxin' and its preparing process | |
| CN1368266A (en) | Nano medicine 'Xuedansu' and its preparing process | |
| CN1364518A (en) | Nano pittecellobium clypearia Benth anti-imflammatory medicine and its preparing method | |
| CN1363339A (en) | Nano medicine 'Compound Kendir' and its preparing process | |
| CN1368296A (en) | Nano medicine 'Yanguo Zhike' and its preparing process | |
| CN1368120A (en) | Nano medicine 'Jinsuanping' and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |